Biocure Technology Inc. is a biopharmaceutical company comprised of leading scientists specializing in the development and commercialization of its own CAR T-cell therapy, targeting Chronic lymphocytic leukemia and solid tumor cancers. Additionally, the Company is developing Biosimilar technologies for cancer treatment. The CAR T-cell cancer therapy space is one of the most innovative cancer treatments currently in the market and is seeing huge global interest.

Founders and management are driven by a social agenda aimed at providing a global answer to highly priced biological medicines that remain outside the reach of common people. The company has unique scientific and execution skills to address the high barriers of CAR-T cell therapy and  Biosimilar technologies, therefore is well positioned to gain leadership in the rapidly growing market of CAR T-cell cancer therapy.

Dr. Sang Mok Lee, CEO & Founder, Director

• President and CEO of Biocure Technology since the inception in 2005
• Holds a PhD in microbiology from Busan National University in Korea and is currently an adjunct professor in microbiology at Chungnam National University

• A committee member for the hi-tech medical complex city in Daejon, Korea and a committee member of KOFST (the Korean Federation of Science and Technology Societies)

Dr. Bjorn Cochlovius, President

• Bjoern Cochlovius, Ph.D,. is a Molecular Biologist and Associate Professor for Immunology at Heidelberg University, Heidelberg, Germany.
• Bjoern has held various leadership positions in biotech (e.g. Affitech, Oslo) and big pharma (amongst others at Roche, Basel; Abbvie, Singapore) in R&D, BD&L and strategic positions.
• Currently holds two chairmanships (Sapreme, Netherlands, and Karolinska Development, Sweden).

Mr. Konstant Lichtenwald, CFO, Director

• Over 15 years’ finance and accounting experience, including corporate compliance, accounting and financial management and IPO, RTO services.
• Extensive knowledge and know-how for companies in North America and German speaking parts of Europe.
• A Chartered Professional Accountant (CPA, CGA) and Chartered Certified Accountant (ACCA), where he is a member of Chartered Professional Accountants of B.C. and Canada as well as a member of the Association of Chartered Certified Accountants of United Kingdom.

Mr. Collin (Sang Goo) Kim, Director

• Holds a bachelor degree of business administration from Korea University, Seoul, Korea.

• Moved to Vancouver, Canada in 2006 after working for Hanwha Corp., one of Korean business conglomerates for 16 years, where he was dedicated to International trading business.
• Vice President for Columbia Capital since 2008 and a director of ArcPacific Resources Corp., a public Canadian junior exploration company, since 2015.
• Communicates between Korean management and Canadian management cross the border with his vast knowledge and work experience.

Mr. Berkan Unal, Director

• Over 10 years’ experience in the biopharmaceutical industry in Germany and Switzerland and connections to global leaders in the biopharmaceutical sector.
• Currently, acts as business development director for biologics, gene and cell therapy of GenScript Biotech, a global leading biotech company, and has been involved in the processes that provide end-to-end solutions from discovery to commercialization.
• Studied bioprocess engineering and medical biotechnology at Berlin Technical University of Applied Sciences, Hamburg University of Technology and Imperial College London

Dr. Danny Joh, Director

• 20 years’ biopharma product development and cross-functional program  management experiences with Chiron, Genentech, Biomarin, Sangamo and other biotech companies.

• Experience spans from early to late stage product development in various platforms, including biologics, small molecules, and gene therapy across many therapeutic areas, including cancer and rare genetic disorders.

• PhD in Biochemistry at Texas A&M university and an MBA at Rice University.

JAE SOO SHIN, PH. D., MANAGING DIRECTOR OF IL-YANG PHARM. CO. LTD. KOREA
‍
Mr. Shin is a pharmacist and also holds a Ph.D. in Pharmacology from Seoul National University in Korea and is currently an adjunct professor at KonKuk University Medical School. He had worked as a chief of pharmacology & toxicology Lab. in the preclinical development of new drugs in Chong Kun Dang Pharmaceutical Corp. for 21 years. Since 2008, he has been working as a managing director for IL-YANG Pharm. Co. Ltd., is responsible for preclinical and clinical development of new drugs and several vaccines for human and avian influenza. Since 2013, he has also been a member of the policy advisory committee of KSAP (The Korean Society of Applied Pharmacology).

HEON JU LEE, PH.D.
‍
Dr. Lee holds Bachelor’s and Master’s degrees in Microbiology from Seoul National University in Korea and a Ph.D. in Environmental Toxicology from Hankuk University of Foreign Studies. For 29 years, he worked on the development of biopharmaceuticals in CJ Inc. and Samsung Group; and conducted nonclinical animal testing and licensing work for drug development in Korea Institute of Toxicology. Currently, he is the vice-president of BiocurePharm, leading the pre-clinical and clinical development of biopharmaceuticals such as interferon beta and CAR-T immune cell therapy products. Since 2011, he has been a member of the Institutional Review Board (IRB) and a Certified Toxicology Professional in Korea.

HYUN SOO LEE, PH.D.
‍
Dr. Lee holds a Ph.D. in molecular biotechnology from Korea Advanced Institute of Science and Technology in Korea. He has worked as a senior researcher in charge of the development of a variety of biopharmaceuticals in CJ Inc. (1987 ~ 2005), and as Director of the Research Institute of JW Creagene Inc. (2005 ~ 2012) developing immune-cell therapies. He is currently Director of the Research Institute of Pharos Vaccine Inc. and a non-executive director of Aprogen Inc.